Society for Clinical Research Sites Experiences Extraordinary Response to Global Impact Partner Program; Pfizer, GSK, Quintiles, and More to Join SCRS' Commitment to Site Success SCRS Global Impact Partner Program Welcomes: DrugDev, EMD Serono, Forte Research Systems, GlaxoSmithKline, HealthCarePoint, IntegReview IRB, Janssen, Merge Healthcare, Pfizer, Quintiles.
ROCKVILLE, Md., Oct. 3, 2013 /PRNewswire/ -- New organizations representing sponsors, CROs, and clinical service providers continue to join the SCRS' Global Impact Partner (GIP) program. SCRS will host the first GIP Board meeting at the upcoming 2013 Site Solutions Summit. Since launching the GIP program in June of this year, SCRS has welcomed more than 20 organizations to join the society's commitment to global clinical research site success. SCRS GIPs will provide ongoing support to the SCRS mission, and help to ensure industry initiatives include the voice of clinical research sites.
The GIP Board will work in tandem with SCRS' Leadership Council to identify the work streams most significant to ensure the success of the research sites around the globe. Each GIP member has appointed one executive to represent their organization while making a two year commitment to the GIP program. The initial GIP work streams will be agreed upon and launched following this year's Site Solutions Summit.
The new GIP industry members, EMD Serono, GlaxoSmithKline, Janssen, Pfizer, and Quintiles will join founding partners Amgen, AstraZeneca, Eli Lilly, PPD, and Roche.
New GIP professional partners include: Drug Dev, Forte Research Systems, HealthCarePoint, IntegReview IRB, and Merge Healthcare will join founding partners: Acurian, Aspire IRB, Clinical Conductor, CFS Clinical, Clinical Site Services, DAC Patient Recruitment Services, and ePharmaSolutions.
SCRS President, Christine Pierre explains "Industry continues to respond favorably to a unified community of sites, and the idea that sites should no longer be the underrepresented partner in the clinical research process. Sites represent a critical link between industry and patient, and have an incredible stake in every step of clinical discovery. Having this unified voice will provide process and operational efficiencies that will improve sustainability for everyone involved in clinical research. Not only is SCRS now representing sites in 22 countries, but within just 6 months of launching its GIP program, to have more than 20 GIP partners is affirmation that these companies are showing their commitment to the sites. SCRS looks forward to working with current and future GIP partners to ensure all industry views are considered towards strengthening the site community."
SCRS is a trade organization representing global clinical research sites representing 1,300 sites in 22 countries in just a little less than a year of its launch. SCRS' mission is to unify and amplify the voice of the global clinical research site community. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will also benefit from membership. Visit www.myscrs.org.
SOURCE The Society for Clinical Research Sites (SCRS)